Small molecule · Inhibitor of exportin 1 (CRM1/XPO1) (XPO1) · developed by Karyopharm Theraps
Selinexor is an oral nuclear export inhibitor that blocks exportin 1 (XPO1, also called CRM1), causing tumor suppressor proteins to accumulate in the nucleus and cancer cells to undergo cell cycle arrest and apoptosis. It is used in multiple myeloma and is studied in several leukemias, lymphoma, myelofibrosis, thrombocytopenia and sarcoma.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 12, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05028348 | Phase 3 | Multiple Myeloma | Active not recruiting | KPTI |
| NCT04442022 | Phase 2/3 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Active not recruiting | KPTI |
| NCT05980806 | Phase 2 | Myelofibrosis | Recruiting | KPTI |
| NCT04717700 | Phase 2 | Multiple Myeloma | Active not recruiting | KPTI |
| NCT04661137 | Phase 2 | Multiple Myeloma | Recruiting | KPTI |
| NCT03732703 | Phase 1/2 | Relapsed Refractory Multiple Myeloma | Completed | KPTI |
| NCT03193437 | Phase 2 | Thymoma | Terminated | KPTI |
| NCT02091245 | Phase 1 | Relapsed Acute Lymphoblastic Leukemia (ALL) | Active not recruiting | KPTI |
| NCT01896505 | Phase 1 | Sarcoma | Completed | KPTI |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Myelogenous Leukemia (CML) in Blast CrisisMild ThrombocytopeniaModerate ThrombocytopeniaMultiple MyelomaMyelofibrosisRefractory Acute Lymphoblastic Leukemia (ALL)Refractory Acute Myelogenous Leukemia (AML)Refractory Biphenotypic LeukemiaRefractory Mixed Lineage LeukemiaRelapsed Acute Lymphoblastic Leukemia (ALL)Relapsed Acute Myelogenous Leukemia (AML)Relapsed Biphenotypic LeukemiaRelapsed Mixed Lineage LeukemiaRelapsed/Refractory Diffuse Large B-cell Lymphoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the KPTI page.
See KPTI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KPTI catalysts and pipeline →